• Science & evidence
• Wellness
• FDA

Semaglutide and the liver: what the ESSENCE trial showed, what's being presented in Denver this week, and what's still unknown

By Peptide Policy Watch staff · Published November 5, 2026 · Updated November 7, 2026 · 8 min read · 9 sources, 9 checked at the source

Most people find out about fatty liver disease by accident: a routine blood test, an ultrasound for something else. The serious form, MASH, can quietly scar the liver for years. A GLP-1 peptide medicine, semaglutide, became one of only two drugs FDA has approved for it, and Novo Nordisk is bringing a dozen new semaglutide liver abstracts to The Liver Meeting in Denver, which runs November 5 to 9, 2026. [V] Here's the evidence so far, in order of strength.

Facts are as of November 5, 2026. Sources, with retrieval dates, are at the bottom.

Updated November 9, 2026. Novo presented the ESSENCE analysis of people with a BMI under 27 on November 8 and released the numbers the same day. [V] It's a post hoc look at 106 people, and liver enzymes and several blood-based scarring markers favored semaglutide over placebo at week 72, while the liver-stiffness scan result was not statistically clear. [V] Details are in the new section Lean MASH: the November 8 numbers below.

Updated November 7, 2026. Novo Nordisk released results from the PLATINUM-Truveta and RHODIUM-2 real-world studies on November 6, and describes both as retrospective. [V] Our brief on Novo's real-world MASH data lays out the numbers and limits, and our real-world evidence explainer covers how much weight that kind of study carries. The ESSENCE BMI-under-27 oral presentation is still listed for Sunday, November 8. [V]

MASH, briefly

MASH stands for metabolic dysfunction-associated steatohepatitis. You may know it by its old name, NASH. FDA describes it as a severe form of fatty liver disease, where fat buildup causes inflammation and scarring that can progress to cirrhosis, liver cancer, transplant or death. [V] Obesity, type 2 diabetes, high triglycerides and high LDL cholesterol all raise the odds. [V] FDA estimates about 6% of U.S. adults, or 14.9 million people, have it. [V] Many people have no symptoms until the damage is advanced. [V]

What ESSENCE found

ESSENCE is a phase 3 trial that enrolled 1,197 adults with biopsy-confirmed MASH and moderate or advanced fibrosis (stages F2 and F3). It randomized them 2:1 to once-weekly semaglutide or placebo. [V] The results published in the New England Journal of Medicine in April 2025 are an interim look at the first 800 participants after 72 weeks. [V]

• 62.9%MASH resolution without worse scarring, vs 34.3% on placebo [V]
• 36.8%less scarring without worse MASH, vs 22.4% on placebo [V]
• 32.7%both at once, vs 16.1% on placebo [V]

Average weight change was -10.5% on semaglutide and -2.0% on placebo. [V] Gastrointestinal side effects were more common with semaglutide. [V] FDA's announcement lists nausea, diarrhea, vomiting and constipation among the most common side effects, and Wegovy carries a warning about thyroid C-cell tumors. [V] Novo funded the trial. [V]

How does it work? FDA says Wegovy "promotes weight loss and potentially other mechanisms not fully understood." [V] That honesty is useful. Nobody can yet say how much of the liver benefit is weight loss and how much is something else.

Why "accelerated" approval matters here

The 72-week results are biopsy readings, a surrogate marker. Accelerated approval lets FDA approve a drug for a serious condition on a marker like that, then requires more data to confirm a real clinical benefit. [V] For ESSENCE, that means part two: whether the biopsy improvements translate into fewer deaths, transplants and other liver events by week 240. [V] Until it reads out, the approval is conditional on that confirmation. [V]

The other approved drug works differently

Rezdiffra (resmetirom) got FDA's first MASH approval, also accelerated, on March 14, 2024. [V] It's a pill that partially activates a thyroid hormone receptor in the liver, so it isn't a peptide. [V] In its phase 3 trial, MAESTRO-NASH, MASH resolution ran 25.9% and 29.9% across the two strengths tested, compared with 9.7% on placebo. [V] FDA lists diarrhea and nausea as common side effects, plus warnings about liver toxicity and gallbladder problems. [V]

Those numbers come from different trials with different people and different biopsy readers. They aren't a head-to-head comparison, so we don't rank the two. Novo's real-world PLATINUM-Truveta poster, covered below, is one of the first attempts to compare them directly, and it isn't a randomized trial. [V]

What's on the program in Denver

Novo's October 28 release lists 12 semaglutide abstracts. [V] The ones drawing the most attention:

• PLATINUM-Truveta compares liver enzymes and cardiometabolic markers in 2,873 people starting semaglutide and 2,285 starting resmetirom across 30 U.S. health systems. It's a poster on Friday, November 6, and AASLD picked it as a Poster of Distinction. [V]
• RHODIUM-2 compares 2,479 semaglutide starters with 70,702 people who didn't start it. [V]
• An ESSENCE post hoc analysis looks at participants with a BMI under 27, in an oral session on Sunday, November 8. [V]
• A phase 2 study tests an experimental combination (zalfermin with cagrilintide and semaglutide) in alcohol-related liver disease. [V]

Novo's October 28 release didn't include results. [V] The PLATINUM-Truveta and RHODIUM-2 results came out on November 6; see our real-world MASH data brief.

Lean MASH: the November 8 numbers

MASH is usually talked about as an obesity disease, but it also shows up in people who aren't heavy. Novo's November 8 release pulled those people out of ESSENCE: of the 800 participants in the trial's 72-week first part, 106 had a BMI below 27. [V] Here is what the company reported for that group, semaglutide versus placebo at week 72. [V]

A ratio under 1, or a difference under 0, leans toward semaglutide. [V] Novo says these marker results add to biopsy findings it has reported in the same subgroup. [V] The study lead, Prof. Jörn Schattenberg of Saarland University, put the takeaway this way in the release: "body size alone does not define MASH." [V]

Two cautions carry over from the box above. First, this is post hoc, a slice chosen after the trial was designed, and Novo itself says such analyses are hypothesis-generating. [V] Second, these are blood and imaging markers, not cirrhosis or survival. Those hard outcomes are what part 2 of ESSENCE is still measuring. [V] Our real-world evidence explainer walks through why the type of analysis matters as much as the headline number.

Limits

The approval covers adults with F2 to F3 fibrosis who don't have cirrhosis. [V] People who already have cirrhosis weren't part of that approval, and treatments for them are a separate research track. [V] The trial combined the drug with diet and exercise advice, so the results describe that package. [V] And compounded semaglutide isn't approved for anything. FDA reviews only the approved product, and the semaglutide shortage that allowed wide compounding was declared over on February 21, 2025. [V] Our GLP-1 explainer covers that difference.

The bigger picture

Five years ago, MASH had no approved drug at all. Now it has two with very different designs, and Novo's own Denver program includes experimental candidates beyond semaglutide. [V] That's real progress, with the hard outcome data still ahead. For the background on how GLP-1 drugs got here, see our peptide medicines timeline. For the next amylin-semaglutide pairing, see our CagriSema explainer, and for reading the studies yourself, the clinical trial listing guide.

Sources (retrieved November 5, 2026)

1. FDA, "FDA Approves Treatment for Serious Liver Disease Known as 'MASH'," August 15, 2025 [V] — https://www.fda.gov/drugs/news-events-human-drugs/fda-approves-treatment-serious-liver-disease-known-mash
2. Sanyal AJ et al., "Phase 3 Trial of Semaglutide in Metabolic Dysfunction-Associated Steatohepatitis," N Engl J Med 2025;392:2089-2099, PMID 40305708 (abstract via Europe PMC) [V] — https://doi.org/10.1056/NEJMoa2413258
3. Novo Nordisk, release on semaglutide MASH and liver data at AASLD The Liver Meeting 2026, October 28, 2026 [V] — https://www.novonordisk-us.com/media/press-releases/novo-nordisk-mash-liver-data-aasld-2026.html
4. FDA, "FDA Approves First Treatment for Patients with Liver Scarring Due to Fatty Liver Disease," March 14, 2024 [V] — https://www.fda.gov/news-events/press-announcements/fda-approves-first-treatment-patients-liver-scarring-due-fatty-liver-disease
5. Harrison SA et al., "A Phase 3, Randomized, Controlled Trial of Resmetirom in NASH with Liver Fibrosis," N Engl J Med 2024, PMID 38324483 (abstract via Europe PMC) [V] — https://pubmed.ncbi.nlm.nih.gov/38324483/
6. FDA, Wegovy supplemental approval letter, NDA 215256/S-024, August 15, 2025 [V] — https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2025/215256Orig1s024ltr.pdf
7. FDA, "FDA clarifies policies for compounders as national GLP-1 supply begins to stabilize," including the February 21, 2025 semaglutide shortage update [V] — https://www.fda.gov/drugs/drug-alerts-and-statements/fda-clarifies-policies-compounders-national-glp-1-supply-begins-stabilize
8. Novo Nordisk, "Novo real-world studies link Wegovy 2.4 mg to reductions in liver enzymes, weight and blood sugar in adults with MASH at The Liver Meeting (AASLD) 2026," PR Newswire, November 6, 2026 (retrieved November 7, 2026) [V] — https://www.prnewswire.com/news-releases/novo-real-world-studies-link-wegovy-2-4-mg-to-reductions-in-liver-enzymes-weight-and-blood-sugar-in-adults-with-mash-at-the-liver-meeting-aasld-2026--302932360.html
9. Novo Nordisk, "Novo post hoc analysis finds Wegovy 2.4 mg was associated with improvements in liver markers in adults with MASH with liver scarring and a BMI less than 27 kg/m2," November 8, 2026 (retrieved November 9, 2026) [V] — https://www.novonordisk.com/news-and-media/news-and-ir-materials/news-details.html?id=920080

Spot a mistake? See how we source and our corrections policy.

Image: AI-generated. Image credits